ArfGAP with GTPase domain, ankyrin repeat and PH domain 11Genealiases: []
Q-omics provides the consensus-scored AGAP11 profile across patient tissues and cancer cell-line models. AGAP11 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, AGAP11 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, AGAP11 RNA expression shows 17,241 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, LUAD, and THYM as cancer lineages where AGAP11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AGAP11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AGAP11 survival associations across molecular data types. AGAP11 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AGAP11 RNA expression–survival associations across cancer types. High AGAP11 expression shows unfavorable associations in DLBC and UVM, but favorable associations in UCS, BLCA, LIHC and LUSC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for AGAP11 RNA expression.
This table summarizes AGAP11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for AGAP11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AGAP11 shows lower tumor expression in LUAD, KICH, BRCA, LUSC and UCEC and higher tumor expression in KIRC. The LUAD box plot shows higher AGAP11 RNA expression in normal versus tumor tissue (log2 FC = −0.401, t-test p < 0.001).
This table shows molecular features associated with AGAP11 in patient tissues and cancer cell lines. In patient samples, AGAP11 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, AGAP11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
